论文部分内容阅读
1981～1988年间曾对100例Dukes B,C和A_3期直肠癌患者进行了术前经直肠腔的5-Fu辅助化疗,每次200mg,平卧保留3小时以上,每日2次,直至术前1天,平均给药22天,总量8.8g,并随机选择同时期、情况基本相同和未进行术前化疗的直肠癌患者100例作为对照组,术后随访2～8年。术前辅助化疗组局部复发率为15％,而对照组为26％,有显著差异(p<0.05)。因此我们认为对Dukes B,C和A_3期直肠癌病人,在放疗设备不够满意的地区和单位,病人在等待住院和术前准备期内应进行经直肠腔的5-Fu辅助化疗,以减少术后局部复发。
Between 1981 and 1988, 100 patients with Dukes B, C, and A_3 rectal cancer were treated with preoperative 5-Fu adjuvant chemotherapy in the rectal cavity, 200 mg each time, and remained in the supine position for more than 3 hours, twice daily until surgery. On the first day, the average dose was 22 days and the total amount was 8.8g. 100 patients with rectal cancer who were at the same time and with the same conditions and no preoperative chemotherapy were randomly selected as the control group. The patients were followed up for 2 to 8 years. The rate of local recurrence in the preoperative adjuvant chemotherapy group was 15%, compared with 26% in the control group, with significant differences (p<0.05). Therefore, we believe that for patients with Dukes B, C, and A_3 rectal cancer, in areas and units that are not satisfied with radiotherapy equipment, the patients should undergo 5-Fu adjuvant chemotherapy in the rectal cavity in order to reduce postoperative hospitalization and preoperative preparation. Local recurrence.